Despite progress made in designing SWM modules in recent years, key issues related to feed-spacer characteristics (particularly spacer material properties in conjunction with their geometry), which affect module performance and membrane integrity, have been neglected by the research community.
The chapter then reviews the progress made in designing injectable hydrogel materials based on self-assembly of nano-scale building blocks and on nanocomposites, focusing on their promising applications in tissue engineering and drug delivery.
Our motive here is to draw attention to the progress made in the design of Qdot-based MB biosensors as we aim to encourage further development in this field and to generate broader interest in Qdot-MB technology.
This article describes progress made in the design of insulin injection needles which have become increasingly shorter, with a thinner outer diameter as well as a thinner wall.
Here we summarize the progress made in the design of FabH inhibitors and the role played by the 3D-structure of the enzyme as well as by the modeling studies in the design of new FabH inhibitors.
This paper outlines progress made in the design of the grounding system, as well as detailing a number of concepts which have been investigated and abandoned, leading up to the current reference design.
In this chapter, I will review the progress made in the design and use of genetic Ca2+ indicators, and discuss how these new tools provide an opportunity to challenge several unsolved questions in Ca2+ signaling.
This article reviews progress made in the design and development of recombinant poxviral-based vaccines that express transgenes for tumor-associated antigens (TAAs) and human T-cell co-stimulatory molecules (designated TRICOM).
In spite of tremendous progress made in pulse sequence designs and sophisticated hardware developments, methods to improve sensitivity and resolution in solid-state NMR (ssNMR) are still emerging.
The progress made in the fields of designing and utilizing small inhibitors of signalling proteins and pulmonary delivery of inhibitory entities makes this possibility very attractive [ 53– 53].
Challenges and opportunities which result from these differences as well as the recent progress made in the optimization of carrier design are presented.
